Health insurance companies may not impose an “arbitrary limit” on coverage for naloxone, a drug used to treat narcotic overdoses, the Department of Financial Services said in a letter to insurers Sept. 28.
In the letter to insurers, the state agency said that naloxone—which blocks or reverses the effects of opioid medications such as oxycodone and fentanyl—must be covered by insurers when medically necessary.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]